Novo Nordisk awards US media mandate to Omnicom, ending WPP partnership
The account, worth over $600 million in annual media spend will transition in Q4 2026
by
Published: Aug 7, 2026 8:57 AM | 1 min read
Follow Us
- Novo Nordisk has appointed Omnicom as its media agency of record for the US, effective Q4 2026, after a competitive review.
- This decision ends Novo Nordisk's long-standing partnership with WPP, which had managed the account since 2020.
- The company's annual US media spend is reported to exceed $600 million, primarily focused on promoting its GLP-1 drugs, including Ozempic and Wegovy.
- The appointment enhances Omnicom's presence in the healthcare marketing sector, aligning with increased media investments by pharmaceutical companies in response to rising demand for obesity and diabetes treatments.
Pharmaceutical giant Novo Nordisk has appointed Omnicom as its media agency of record for the US, following a competitive review, ending its long-standing partnership with WPP.
The new mandate will take effect from the fourth quarter of 2026. WPP's Wavemaker had handled the account since winning the business in 2020.
According to agency research firm COMvergence, Novo Nordisk's annual US media spend exceeds $600 million. The company is best known for its blockbuster GLP-1 drugs, including Ozempic and Wegovy, used to treat diabetes and obesity.
Confirming the appointment, Novo Nordisk said in a statement to international media, "Novo Nordisk has selected Omnicom as our agency-of-record to manage media buying in the U.S. beginning in Q4 2026. We look forward to working with the Omnicom team as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies, helping bring even greater awareness of our medicines to people living with chronic conditions such as obesity and diabetes."
The account win further strengthens Omnicom's position in the healthcare marketing sector, as pharmaceutical companies continue to ramp up media investments amid rising demand for obesity and diabetes treatments.
Read more news about Marketing News, Advertising News, PR and Corporate Communication News, Digital News, People Movement News
For more updates, be socially connected with us onInstagram, LinkedIn, Twitter, Facebook, YouTube & Google News